Bronnen:
- Evans T, Rosenthal ET, Youngblom J, et al. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell. 1983;33:389-96.,Renaudin JP, Doonan JH, Freeman D, et al. Plant cyclins: a unified nomenclature for plant A-,B- and D-type cyclins based on sequence organization. Plant Mol Biol. 1996;32:1003-18.,McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther. 2004;15:1022-33.,Asghar U, Witkiewicz AZ, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130-46.,Dukelow T, Kishan D, Khasraw M, Murphy CG. CDK4/6 inhibitors in breast cancer. Anti-Cancer Drugs. 2015;26:797-806.,Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer treat rev. 2016;45:129-38.,Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical development of the CDK4/6 inhibitors Ribociclib and abemaciclib in breast cancer. Breast Care. 2016;11:167-73.,Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425-39.,Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016; 375:1925-36.,Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738-48,Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209-19.,Cie BOM. Letrozol plus palbociclib als eerste lijns behandeling bij gemetastaseerd hormoonreceptorpositief mammacarcinoom. Medische Oncol. 2017, februari, 35-37.,Honkoop AH, Bloemendal HJ. Advies NABON en NVMO betreffende toepassing palbociclib bij mammacarcinoom. Medische Oncol. 1017, februari: 27.,Wolff AC. CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard. Editorial N Engl J Med. 2016;375:1993-5.